Does Rallies show Form 4 insider transactions for EVH?

Yes. Rallies tracks EVH insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.

Is EVH research on Rallies investment advice?

No. Rallies provides research, data, and educational context for EVH. It does not provide personalized investment advice.

EVH (Evolent Health, Inc Class A Common Stock) Stock Analysis - Insider Trades

Evolent Health, Inc Class A Common Stock (EVH) is a publicly traded Healthcare sector company. As of May 21, 2026, EVH trades at $3.90 with a market cap of $438.68M and a P/E ratio of -0.80. EVH moved -0.64% today. Year to date, EVH is -2.28%; over the trailing twelve months it is -55.99%. Its 52-week range spans $2.10 to $29.59. Analyst consensus is strong buy with an average price target of $5.85. Rallies surfaces EVH's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who is trading EVH stock inside the company?

Recent EVH insider activity includes Springstubb Brendan B bought 10.00K, Jelinek Richard M bought 15.00K, Jelinek Richard M bought 15.00K, Springstubb Brendan B bought 15.00K, and KECK KIM bought 10.54K. Rallies tracks insider transaction dates, shares, prices, and estimated values.

EVH Key Metrics

Key financial metrics for EVH
Metric	Value
Price	$3.90
Market Cap	$438.68M
P/E Ratio	-0.80
EPS	$-4.76
Dividend Yield	0.00%
52-Week High	$29.59
52-Week Low	$2.10
Volume	0
Avg Volume	0
Revenue (TTM)	$1.89B
Net Income	$-533.78M
Gross Margin	20.18%

Recent EVH Insider Trades

Springstubb Brendan B bought 10.00K (~$38.20K) on Nov 18, 2025.
Jelinek Richard M bought 15.00K (~$137.40K) on Mar 7, 2025.
Jelinek Richard M bought 15.00K (~$136.35K) on Mar 7, 2025.
Springstubb Brendan B bought 15.00K (~$139.05K) on Mar 7, 2025.
KECK KIM bought 10.54K (~$99.50K) on Mar 7, 2025.

Latest EVH News

Rosarium Health Secures $6M Seed Round for Faster In-Home Senior Care — May 12, 2026
Quest Analytics Names Chris Lance CPO to Drive AI-Powered Network Management for 400+ Clients — May 12, 2026
Evolent Health Q1 Revenue Rises to $496M; New $200M Oncology, Imaging Deals — May 7, 2026
Evolent Health Plunges 4.7% as Core PPI Jumps 0.8% in January — Feb 27, 2026
Evolent Health Q4 EPS Turns $0.08 vs $0.02 Loss, Shares Up 20.7% — Feb 25, 2026

EVH Analyst Consensus

14 analysts cover EVH: 0 strong buy, 12 buy, 2 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $5.85.

Common questions about EVH

Who is trading EVH stock inside the company?: Recent EVH insider activity includes Springstubb Brendan B bought 10.00K, Jelinek Richard M bought 15.00K, Jelinek Richard M bought 15.00K, Springstubb Brendan B bought 15.00K, and KECK KIM bought 10.54K. Rallies tracks insider transaction dates, shares, prices, and estimated values.
Does Rallies show Form 4 insider transactions for EVH?: Yes. Rallies tracks EVH insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.
Is EVH research on Rallies investment advice?: No. Rallies provides research, data, and educational context for EVH. It does not provide personalized investment advice.